Propanc Biopharma Inc (OTCMKTS:PPCB – Get Free Report) rose 5.3% during trading on Friday . The stock traded as high as $0.29 and last traded at $0.28. Approximately 263,169 shares changed hands during mid-day trading, a decline of 0% from the average daily volume of 263,688 shares. The stock had previously closed at $0.2660.
Propanc Biopharma Stock Performance
The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $0.64 and its two-hundred day moving average is $2.41. The firm has a market capitalization of $3.74 million, a price-to-earnings ratio of -0.01 and a beta of 3.45.
Institutional Investors Weigh In On Propanc Biopharma
An institutional investor recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC acquired a new stake in Propanc Biopharma Inc (OTCMKTS:PPCB – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned about 0.33% of Propanc Biopharma at the end of the most recent reporting period.
About Propanc Biopharma
Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.
The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.
Further Reading
- Five stocks we like better than Propanc Biopharma
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- Your Signature Is Missing – Act Before It’s Too Late
- The $100 Trillion AI Story No One Is Telling You
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
